←Fibromyalgia
Study register · detail Sonstiges · Fibromyalgia · 2021

Cannabidiol Use for Fibromyalgia: Prevalence of Use and Perceptions of Effectiveness in a Large Online Survey

Boehnke et al. ·The Journal of Pain Impact 1.0
Mixed 61 citations
Samplen = 2.701
Durationunclear
EndpointPrevalence of CBD use
Blindingn.a.
DesignSonstiges
Cannabinoidcbd
Key finding

32,4% of fibromyalgia patients report current CBD use with predominantly mild to marked improvements across several symptom domains, however about half report side effects.

Summary

n=2.701 fibromyalgia patients (online survey); 38% report CBD use, of which 72% with subjective symptom improvement (pain, sleep, anxiety); no placebo control, self-selection, exploratory data — real-world perspective on CBD prevalence and perceived efficacy.

P
PopulationAdults with fibromyalgia, n=2.701, primarily USA, online survey
I
InterventionNaturalistic CBD use (various formulations, self-administered)
O
Outcome32,4% current CBD use, 29,4% previous use; majority reports mild to marked improvement across multiple symptom domains (especially pain); ~50% mild side effects
Quality profile
Sample size ★★★★★
Blinding —
Effect size Mixed
Citations / year ★★★★★
Authors
Boehnke K F, Gagnier J J, Matallana L et al.
DOI 10.1016/j.jpain.2020.12.001↗
Design: Sonstiges
Share
Abstract
Perspective: This article indicates that CBD use is common among people with fibromyalgia, and the results suggest that many derive benefit from using CBD across multiple symptoms domains. Clinicians should discuss CBD use with fibromyalgia patients, and future studies are needed to rigorously assess CBD's therapeutic value for fibromyalgia symptoms. by Elsevier Inc. All rights reserved.
Indication
Further studies on Fibromyalgia
All studies →
S Rasmussen et al. · 2026 · Annals of the rheumatic diseases
1 citations
Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Harm RCT

n=200 Fibromyalgie-Patienten, CBD 50 mg täglich vs. Placebo über 24 Wochen; primärer Endpunkt Schmerzintensität (NRS): CBD-Gruppe -0,4 Punkte (95% CI: -0,82 bis 0,08), Placebo-Gruppe -1,1 Punkte (95% CI: -1,53 bis -0,63), Gruppenunterschied -0,7 Punkte (95% CI: -1,2 bis -0,25; p=0,0028) zugunsten Placebo. CBD 50 mg täglich zeigte keine analgetische Wirksamkeit.

10.1016/j.ard.2025.07.008 View study →
S Walitt et al. · 2016 · Cochrane Database of Systematic Reviews
120 citations
Cannabinoids for fibromyalgia
No benefit demonstrated Cochrane Review

Cochrane SR über 2 RCTs (n=72) zu Cannabinoiden bei Fibromyalgie; nabilone vs. Placebo zeigte keine statistisch signifikante Schmerzreduktion oder Verbesserung der Lebensqualität; sehr kleine Stichprobengröße und kurze Studiendauer limitieren Aussagekraft; keine ausreichende Evidenz für Wirksamkeit.

10.1002/14651858.cd011694.pub2 View study →
A Häuser et al. · 2018 · European Journal of Pain
189 citations
European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management
Unclear Leitlinie

EFIC-Positionspapier zur angemessenen Anwendung cannabisbasierter Medikamente bei chronischen Schmerzen; empfiehlt zurückhaltenden Einsatz bei Fibromyalgie aufgrund begrenzter Evidenz (schwache Empfehlung).

10.1002/ejp.1297 View study →

The impediment to action advances action. — Marcus Aurelius